Thursday, 18 April 2024
Trending

[the_ad_group id="2845"]

Investing

JMP Securities rates Werewolf Therapeutics stock Outperform, says platform ‘inovative’ By Investing.com

Here are top 2 U.S. exchange stocks to own according to Atlantic Equities

[the_ad id="21475"]

[ad_1]

On Wednesday, JMP Securities initiated coverage on Werewolf Therapeutics Inc. (NASDAQ:HOWL) stock with a Market Outperform rating and set a price target of $12.00. The firm believes that Werewolf’s proprietary PREDATOR platform could mark a new chapter in the field of immunotherapy.

Werewolf Therapeutics, a biotechnology company, has been recognized for its innovative approach to cytokine-based therapies. JMP Securities’ evaluation is based on a combination of discounted earnings per share and revenue multiple analysis. This assessment reflects confidence in the company’s potential to overcome the challenges that have historically impeded the success of cytokine therapies in biotechnology.

The company’s lead product candidate, WTX-124, has demonstrated promising differentiation in preclinical trials when compared to the administration of IL-2. These results underpin the analyst’s positive outlook. Werewolf Therapeutics is also anticipated to release monotherapy dose-escalation results for WTX-124 and WTX-330 in the first half of 2024.

A strategic partnership with Jazz Pharmaceuticals (NASDAQ:) and a strong cash position, reported at $134.3 million, further bolster the company’s standing in the eyes of JMP Securities. The firm’s analysis suggests that Werewolf Therapeutics’ shares are currently undervalued, presenting an investment opportunity with a significant potential upside of approximately 296% and a downside risk of around 83%.

InvestingPro Insights

Werewolf Therapeutics Inc. (NASDAQ:HOWL) has caught the attention of JMP Securities, and a closer look at the company through InvestingPro’s lens provides additional insights. With a market capitalization of $258.99 million, the company holds a notable position in the biotech sector. However, InvestingPro data reveals a challenging financial landscape with a negative P/E ratio of -5.72, indicating that the company is not currently profitable. This is further supported by a gross profit margin of -95.09% for the last twelve months as of Q4 2023, suggesting significant costs relative to revenue.

InvestingPro Tips highlight that Werewolf Therapeutics holds more cash than debt, which is a positive sign of financial health. Moreover, the company’s liquid assets surpass its short-term obligations, providing some financial flexibility. Despite these strengths, analysts do not expect the company to be profitable this year, and a sales decline is anticipated. Yet, the stock has experienced a strong return over…

Click Here to Read the Full Original Article at All News…

[ad_2]

[the_ad id="21476"]